Could Biocept (BIOC) spike once more?
Biocept (BIOC) currently trades at $0.39 and has fallen by 6.17% today. BIOC went down $0.2 from the previous closing price of $0.42. The high forecast for Biocept is $1.00 and the low is $0.15. The company’s market cap is $51.60 million with a 52 week high of $2.11 and a 52 week low of $0.21. BIOC has changed in price by -0.62 per share in the last 12 months. The company has recently sold 22.3M common shares at $0.46 per share, for gross proceeds of ~$10.3M, in a registered direct offering.
Biocept has a weak EPS of -1.22. This means the company lost $-1.22 per share after paying dividends, this can indicate that the stock is a risky investment. EPS is calculated as a company’s profit divided by the outstanding shares of its common stock. The resulting number serves as an indicator of a company’s profitability. It is common for a company to report EPS that is adjusted for extraordinary items and potential share dilution. Based on this information, investorsQ rates this stock 4 out of 10. We give it this rating based on current information written in this article. The probability of a spike is very unlikely for Biocept’s case.
Biocept, Inc. is a commercial-stage cancer diagnostics company. The Company focuses on developing and commercialization proprietary circulating tumor cell and circulating tumor DNA tests. Biocept serves patients and customers in the State of California.